KÁTIA LUZ TORRES

Prof. Dr. KÁTIA LUZ TORRES

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2007 in Experimental Parasitology
Verified
Journal Article
Closed access
BGBianca E. Gama
Bianca E. Gama
FSFelipe Do E.S. Silva-Pires
Felipe Do E.S. Silva-Pires
MLMauro N’kRuman R. Lopes
Mauro N’kRuman R. Lopes
MCMaria Angélica B. Cardoso
Maria Angélica B. Cardoso
Constança BrittoConstança Britto
Constança Britto
MFMaria de Fátima Ferreira-Da-Cruz
Maria de Fátima Ferreira-Da-Cruz

17 February 2018 in Virology Journal
Verified
Journal Article
Open access
PDF file
MTMonique Figueiredo Teixeira
Monique Figueiredo Teixeira
MSMeritxell Sabidó
Meritxell Sabidó
ALAndré Luiz Leturiondo
André Luiz Leturiondo
CFCynthia de Oliveira Ferreira
Cynthia de Oliveira Ferreira
KÁTIA LUZ TORRESKÁTIA LUZ TORRES
KÁTIA LUZ TORRES
ABAdele Schwartz Benzaken
Adele Schwartz Benzaken
Human immunodeficiency virus (HIV)-positive women have a high prevalence of human papillomavirus (HPV), and are infected with a broader range of HPV types than HIV-negative women. We aimed to determine the prevalence of cervical cytologic abnormalities, high-risk (HR)-HPV prevalence, type distribution according to the severity of cervical lesions and CD4 cell count and identify factors associated with HR-HPV infection among women living with HIV in Manaus, Amazonas. We enrolled 325 women living with HIV that attended an infectious diseases referral hospital. Each woman underwent a gynecological exam, cervical cytology, HR-HPV detection by Polymerase chain Reaction (PCR) using the BD Onclarity™ HPV Assay, colposcopy and biopsy, when necessary. We assessed the associations between potential risk factors and HR-HPV infection. Overall, 299 (92.0%) women had a PCR result. The prevalence of HR-HPV- infection was 31.1%. The most prevalent HR-HPV types were: 56/59/66 (32.2%), 35/39/68 (28.0%), 52 (21.5%), 16 (19.4%), and 45 (12.9%). Among the women with HR-HPV infection (n = 93), 43.0% had multiple infections. Women with HPV infection showed higher prevalence of cervical abnormalities than that HPV-negative (LSIL: 22.6% vs. 1.5%; HSIL: 10.8% vs. 0.0%). The prevalence of HR-HPV among women with cytological abnormalities was 87.5% for LSIL and 100.0% for HSIL. Women with CD4 < 200 cell/mm3 showed the highest HR-HPV prevalence (59.3%) although this trend was not statistically significant (p-value = 0.62). The mean CD4 cell count decreased with increasing severity of cervical lesions (p-value = 0.001). The multivariable analysis showed that increasing age was associated with a decreased risk of HR-HPV infection with an adjusted prevalence odds ratio of 0.9 (95.0% CI: 0.9–1.0, p-value: 0.03) for each additional year. The only factor statistically significant associated with HR-HPV infection was CD4 cell count. HR-HPV and abnormal cytology prevalence are high among women in the Amazonas. The low CD4 cell count was an important determinant of HPV infection and abnormal cytological findings. HPV quadrivalent vaccination used in Brazil might not offer protection for an important fraction of HPV-related disease burden in women living with HIV. This is partly explained by the high presence of non targeted vaccine HR-HPVs, such as the HPV genotype groups 56/59/66, 35/39/68 and individually HPV-52 and HPV-45, some of which contribute to high-grade lesion.

26 November 2007 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
MNMaria Claudia Nascimento
Maria Claudia Nascimento
PMPhilippe Mayaud
Philippe Mayaud
ESEster Cerdeira Sabino
Ester Cerdeira Sabino
KÁTIA LUZ TORRESKÁTIA LUZ TORRES
KÁTIA LUZ TORRES
SFSilvia Franceschi
Silvia Franceschi
Little data are available on the seroprevalence of, and risk factors for hepatitis B and C viruses (HBV and HCV) infection in Latin American countries. A multi‐center serosurvey was conducted among 3,598 first‐time blood donors (65% men) from Sao Paulo, Salvador and Manaus in Brazil. The gender‐specific seroprevalences of antibodies against hepatitis B core antigen (anti‐HBc) and of the hepatitis B surface antigen (HBsAg) in anti‐HBc‐positive sera were measured, and risk factors analyzed by gender. The gender‐specific seroprevalences of antibodies against HCV (anti‐HCV) were measured, but risk factors for HCV were not determined. Anti‐HBc and HBsAg seroprevalences were not significantly different in men [101/2,341 (4.31%) and 4/2,229 (0.18%), respectively] and women [65/1,237 (5.25%) and 8/1,169 (0.68%), respectively], whereas the seroprevalence of anti‐HCV was higher in women (12/1,238 [0.97%] vs. 9/2,353 [0.38%]; odds ratio [OR] = 2.49; 95% confidence interval [CI]: 1.0–6.0). No significant difference for HBV infection was found across the three study sites or by ethnic group. The seroprevalence of anti‐HBc increased with age, but decreased with education level in both genders. Lifetime number of sexual partners was associated with anti‐HBc prevalence among men (OR = 1.95; 95% CI: 1.2–3.1), but not women. The seroprevalence of HBV and HCV was low among Brazilian blood donors, and exposure increased with age in both genders. J. Med. Virol. 80:53–57, 2008.

23 July 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KÁTIA LUZ TORRESKÁTIA LUZ TORRES
KÁTIA LUZ TORRES
JMJosiane Montanho Mariño
Josiane Montanho Mariño
DRDanielle Albuquerque Pires Rocha
Danielle Albuquerque Pires Rocha
MMMônica Bandeira De Mello
Mônica Bandeira De Mello
HFHeydy Halanna De Melo Farah
Heydy Halanna De Melo Farah
JLJosé Eduardo Levi
José Eduardo Levi
To evaluate both the performance and acceptability of a method coupling self-sampling with detection of cervical malignancy via elevated HPV 16 and 18 E6 oncoproteins (OncoE6™ Cervical Test) in remote areas in Brazil. Women living in rural villages in proximity to Coari city, Amazonas, Brazil were invited to participate in a cervical cancer screening study. 412 subjects were enrolled; there were no refusals. In addition to E6 protein detection, DNA was extracted from the brushes and evaluated for HPV genotypes by PCR (PGMY09/11), followed by typing by the Papillocheck™ if positive. Subjects who were found to be positive for OncoE6 or HPV-DNA were referred for colposcopy. For 110 subjects (27%) this was the first cervical cancer exam. Overall the HPV-DNA prevalence was 19.1% (n = 79); 1.4% (n = 6) were positive by the OncoE6 Test. Fifty-six women attended the invitation for colposcopy where nine had an abnormal cervix and were subsequently biopsied. Histopathological analysis revealed 2 CIN3, 2 carcinomas and 5 CIN1. OncoE6 called two out of the three HPV 16 or 18 associated CIN3+ lesions. The findings suggest that self-administered sample collection in combination with OncoE6 Test is feasible in this population. This could enable expanded screening coverage while ensuring a high specificity which is imperative given the remote geographic location, since women bearing abnormal test results would necessitate travel and logistical burden to access colposcopy and treatment.


21 February 2014 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
MMM. N. dos S. Moresco
M. N. dos S. Moresco
HVH. de A. Virgolino
H. de A. Virgolino
MMM. P. E. de Morais
M. P. E. de Morais
IMI. da Motta‐Passos
I. da Motta‐Passos
MGM. S. Gomes‐Gouvêa
M. S. Gomes‐Gouvêa
KÁTIA LUZ TORRESKÁTIA LUZ TORRES
KÁTIA LUZ TORRES